Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2016; 37(03): 168-173
DOI: 10.4103/0971-5851.190362
ORIGINAL ARTICLE

Newly established stem cell transplant program: 100 days follow-up of patients and its comparison with published Indian literature

Aseem Kumar Tiwari
Department of Transfusion Medicine, Medanta - The Medicity, Gurgaon, Haryana, India
,
Dinesh Arora
Department of Transfusion Medicine, Medanta - The Medicity, Gurgaon, Haryana, India
,
Ravi C Dara
Department of Transfusion Medicine, Medanta - The Medicity, Gurgaon, Haryana, India
,
Pranav Dorwal
Department of Molecular Genetics and Immunology, Medanta - The Medicity, Gurgaon, Haryana, India
,
Nitin Sood
Department of Medical and Hemato-oncology, Medanta - The Medicity, Gurgaon, Haryana, India
,
Ruchira Misra
Department of Paediatric Medical and Hemato-oncology, Medanta - The Medicity, Gurgaon, Haryana, India
,
Sunil Kumar Gupta
Department of Medical and Hemato-oncology, Medanta - The Medicity, Gurgaon, Haryana, India
,
Vimarsh Raina
Laboratory Services and Transfusion Medicine, Medanta - The Medicity, Gurgaon, Haryana, India
,
Ashok Kumar Vaid
Department of Medical and Hemato-oncology, Medanta - The Medicity, Gurgaon, Haryana, India
› Author Affiliations Financial support and sponsorship Nil.
› Further Information
Also available at
  PDF Download Permissions and Reprints

Abstract

Background: Hematopoietic progenitor stem cell transplantation (HPSCT) is used as a standard treatment option to improve outcome in hematological and nonhematological disorders. It is important for new HPSCT program to look at its patient outcome data and compare it with the published data to evaluate the efficacy of program. Aims: The aim was to compile and collate the patient outcome data of HPSCT and compare with published reports. Materials and Methods: Patient demographics, indications, stem cell harvest by apheresis, dose collected, infusion, engraftment, and follow-up data were collected from hospital information system from 2010 to 2013 in a tertiary care hospital. HPSCs were mobilized with granulocyte colony-stimulating factor, and harvests were done on the 5th day. Engraftment was decided for neutrophil when counts were 0.5 × 109/L and for platelets when counts were 20 × 109/L on two consecutive days without any transfusion support. Results: There were 133 harvests for 95 patients with various disorders; multiple myeloma was most common in autologous and acute lymphoblastic leukemia in allogeneic group. One hundred harvests were done for autologous and 33 for allogeneic HPSCT. In autologous group, of 66 patients, 60 (90.9%) received stem cell infusion at median dose of 4.63 × 106 CD34+ cells/kg. Similarly, in allogeneic group, of 29 patients, 27 (93.10%) received infusion at median dose of 5.8 × 106 CD34+ cells/kg. 58 (96.9%) patients and 25 (92.6%) engrafted in autologous and allogeneic group, respectively. The median time for neutrophils engraftment was 11 days in autologous group and 12 days in allogeneic group. The median time for platelet engraftment was 11.5 days in autologous group and 13 days in allogeneic group. The 100-day survival rate was 95% n = 57) in autologous group and 77.8% n = 21) in allogeneic group. Conclusion: This data analysis shows reasonably good results of HPSCTs with majority of patients surviving at 100-day follow-up.

Keywords

Follow-up - hematopoietic progenitor stem cell transplants - mortality - peripheral blood stem cells - stem cell transplant program - survival - transplant


Publication History

Article published online:
12 July 2021

© 2016. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Thomas ED. Bone marrow transplantation: A review. Semin Hematol 1999;36 4 Suppl 7:95-103.
  • 2 Forman SJ, Blume KG, Thomas ED, editors. Hematopoietic Cell Transplantation. 2nd ed. London, New York: Blackwell Scientific Publishers Inc.; 1998.
  • 3 Craddock C. Haemopoietic stem-cell transplantation: Recent progress and future promise. Lancet Oncol 2000;1:227-34.
  • 4 Urbano-Ispizua A, Schmitz N, de Witte T, Frassoni F, Rosti G, Schrezenmeier H, et al. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: Definitions and current practice in Europe. Bone Marrow Transplant 2002;29:639-46.
  • 5 Gratwohl A, Baldomero H, Horisberger B, Schmid C, Passweg J, Urbano-Ispizua A; Accreditation Committee of the European Group for Blood and Marrow Transplantation (EBMT). Current trends in hematopoietic stem cell transplantation in Europe. Blood 2002;100:2374-86.
  • 6 Kyle RA, Rajkumar SV. Multiple myeloma. Blood 2008;111:2962-72.
  • 7 Körbling M, Przepiorka D, Huh YO, Engel H, van Besien K, Giralt S, et al. Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: Potential advantage of blood over marrow allografts. Blood 1995;85:1659-65.
  • 8 Russell JA, Bowen T, Brown C, Luider J, Ruether JD, Stewart D, et al. Second allogeneic transplants for leukemia using blood instead of bone marrow as a source of hemopoietic cells. Bone Marrow Transplant 1996;18:501-5.
  • 9 Bensinger WI, Clift R, Martin P, Appelbaum FR, Demirer T, Gooley T, et al. Allogeneic peripheral blood stem cell transplantation in patients with advanced hematologic malignancies: A retrospective comparison with marrow transplantation. Blood 1996;88:2794-800.
  • 10 Russell JA, Brown C, Bowen T, Luider J, Ruether JD, Stewart D, et al. Allogeneic blood cell transplants for haematological malignancy: Preliminary comparison of outcomes with bone marrow transplantation. Bone Marrow Transplant 1996;17:703-8.
  • 11 Schmitz N, Bacigalupo A, Labopin M, Majolino I, Laporte JP, Brinch L, et al. Transplantation of peripheral blood progenitor cells from HLA-identical sibling donors. European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol 1996;95:715-23.
  • 12 Korbling M, Mirza N, Przepiorka D, Anderlini P, Chan KW, Champlin, R. Clinical outcome in 112 patients following HLA-identical allogenic peripheral blood stem cell (PBSC). Blood 1997;10(Suppl. 1):224a-225a.
  • 13 Miflin G, Russell NH, Hutchinson RM, Morgan G, Potter M, Pagliuca A, et al. Allogeneic peripheral blood stem cell transplantation for haematological malignancies – An analysis of kinetics of engraftment and GVHD risk. Bone Marrow Transplant 1997;19:9-13.
  • 14 Vigorito AC, Azevedo WM, Marques JF, Azevedo AM, Eid KA, Aranha FJ, et al. A randomised, prospective comparison of allogeneic bone marrow and peripheral blood progenitor cell transplantation in the treatment of haematological malignancies. Bone Marrow Transplant 1998;22:1145-51.
  • 15 Brown RA, Adkins D, Khoury H, Vij R, Goodnough LT, Shenoy S, et al. Long-term follow-up of high-risk allogeneic peripheral-blood stem-cell transplant recipients: Graft-versus-host disease and transplant-related mortality. J Clin Oncol 1999;17:806-12.
  • 16 Champlin RE, Schmitz N, Horowitz MM, Chapuis B, Chopra R, Cornelissen JJ, et al. Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogenic transplantation. IBMTR Histocompatibility and Stem Sources Working Committee and the European Group for Blood and Bone Marrow Transplantation (EBMT). Blood 2000;95:3702-9.
  • 17 Bensinger WI, Martin PJ, Storer B, Clift R, Forman SJ, Negrin R, et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 2001;344:175-81.
  • 18 Gratwohl A, Baldomero H, Aljurf M, Pasquini MC, Bouzas LF, Yoshimi A, et al. Hematopoietic stem cell transplantation: A global perspective. JAMA 2010;303:1617-24.
  • 19 Chandy M. Stem cell transplantation in India. Bone Marrow Transplant 2008;42 Suppl 1:S81-4.
  • 20 Kumar L, Ganessan P, Ghosh I, Panda D, Gogia A, Mandhania S. Autologous blood stem cell transplantation for Hodgkin and non-Hodgkin lymphoma: Complications and outcome. Natl Med J India 2010;23:330-5.
  • 21 Kumar L, Malik PS, Prakash G, Prabu R, Radhakrishnan V, Katyal S, et al. Autologous hematopoietic stem cell transplantation-what determines the outcome: An experience from North India. Ann Hematol 2011;90:1317-28.
  • 22 Kumar L, Cyriac SL, Tejomurtula TV, Bahl A, Biswas B, Sahoo RK, et al. Autologous stem cell transplantation for multiple myeloma: Identification of prognostic factors. Clin Lymphoma Myeloma Leuk 2013;13:32-41.
  • 23 Seth T, Kanga U, Sood P, Sharma V, Mishra P, Mahapatra M. Audit of peripheral stem cell transplantation for aplastic anemia in multitransfused infected patients. Transplant Proc 2012;44:922-4.
  • 24 Nair V, Sharma A, DAS S, Sharma S, Grover N, Kaur J. Allogeneic haematopoietic stem cell transplantation: The Army hospital experience. Natl Med J India 2013;26:6-11.
  • 25 Leung W, Pui CH, Coustan-Smith E, Yang J, Pei D, Gan K, et al. Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia. Blood 2012;120:468-72.
  • 26 Duong HK, Savani BN, Copelan E, Devine S, Costa LJ, Wingard JR, et al. Peripheral blood progenitor cell mobilization for autologous and allogeneic hematopoietic cell transplantation: Guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2014;20:1262-73.
  • 27 Sezer O, Possinger K, Metzner B, Illiger HJ, Wattad M, Heit W, et al. Optimal CD34(+) cell dose in autologous peripheral-blood stem-cell transplantation. J Clin Oncol 2000;18:3319-20.
  • 28 Mehta J, Mehta J, Frankfurt O, Altman J, Evens A, Tallman M, et al. Optimizing the CD34+cell dose for reduced-intensity allogeneic hematopoietic stem cell transplantation. Leuk Lymphoma 2009;50:1434-41.
  • 29 Sutherland DR, Anderson L, Keeney M, Nayar R, Chin-Yee I. The ISHAGE guidelines for CD34+cell determination by flow cytometry. International Society of Hematotherapy and Graft Engineering. J Hematother 1996;5:213-26.
  • 30 Berz D, McCormack EM, Winer ES, Colvin GA, Quesenberry PJ. Cryopreservation of hematopoietic stem cells. Am J Hematol 2007;82:463-72.
  • 31 Sartor M, Antonenas V, Garvin F, Webb M, Bradstock KF. Recovery of viable CD34+cells from cryopreserved hemopoietic progenitor cell products. Bone Marrow Transplant 2005;36:199-204.
  • 32 Wingard J.R, Gastineau D.A, Leather HL, Snyder E, Szczepiorkowski ZM. Hematopoietic Stem Cell Transplantation: A Handbook for Clinicians. Bethesda, Maryland: AABB; 2009.
  • 33 Gajewski JL, Johnson VV, Sandler SG, Sayegh A, Klumpp TR. A review of transfusion practice before, during, and after hematopoietic progenitor cell transplantation. Blood 2008;112:3036-47.